PTPA and ischemic cardiomyopathy: We suggest that the results obtained for the TM54 mouse may reflect the potential of PP2A anchoring disruptor therapy to treat DCM of different etiologies, especially given the beneficial effects AAV9sc.PBD, as well as mAKAPβ scaffold gene targeting, exhibited previously in ischemic cardiomyopathy.7